OTLK News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

OT

Mkt Cap

$119.0M

Volume

3.05M

Loading chart

OT

OTLKOutlook Therapeutics, Inc. Common Stock

OTLK

Pay with—

Available Balance0.00

OT

Mkt Cap

$121.7M

Volume

3.05M

Next Earnings

N/A

Chart Financials Earnings News About Insider Filings

LYTENAVA Sales Forecast and Market Size Analysis 2020-2034: FDA Setback Shapes LYTENAVA Commercial PathOutlook Therapeutics' LYTENAVA (bevacizumab gamma) received a Complete Response Letter from the FDA in December 2025, preventing approval for wet AMD treatment in the US. The drug is approved in Europe and positioned as a mid-priced alternative between compounded bevacizumab and premium anti-VEGF therapies, with potential expansion into branch retinal vein occlusion and diabetic macular edema indications.GlobeNewswire Inc. · Sep 10, 2026

Outlook Therapeutics Announces LYTENAVA™ FDA Approval as the First and Only FDA-Approved Ophthalmic Bevacizumab for the Treatment of Wet AMDOutlook Therapeutics announced FDA approval of LYTENAVA™ (bevacizumab-vikg), the first FDA-approved ophthalmic formulation of bevacizumab specifically designed for treating wet AMD. The approval provides 12 years of market exclusivity under BPCIA and positions the company to capture market share in the approximately $8.5 billion U.S. retina market. The company is launching commercial operations and expects to make LYTENAVA™ available to patients before year-end.GlobeNewswire Inc. · Jul 24, 2026

Outlook Therapeutics Announces Pricing of $5.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesOutlook Therapeutics announced a $5.0 million registered direct offering of 8.5 million shares at $0.5855 per share to its largest stockholder GMS Ventures and Investments. The company also agreed to amend outstanding warrants held by GMS Ventures, reducing the exercise price from $1.78 to $0.5855 per share. Proceeds will be used for working capital and general corporate purposes.GlobeNewswire Inc. · May 28, 2026

Outlook Therapeutics Announces Proposed Public OfferingOutlook Therapeutics (NASDAQ: OTLK) announced a best-efforts public offering of common stock and accompanying warrants to raise capital for working capital and general corporate purposes. H.C. Wainwright & Co. is serving as the exclusive placement agent. The offering is subject to market conditions with no assurance of completion timing or terms.Benzinga · Mar 23, 2026

Stock Market Today: S&P 500, Dow Futures Gain On The First Trading Day Of 2026— Baidu, Rubico, Intelligent Bio Solutions In FocusU.S. stock futures rose on the first trading day of 2026, with the S&P 500 and Nasdaq 100 gaining in premarket trading. Key movers included Baidu jumping 12.2% on a spinoff announcement, Rubico surging 16.8% following an acquisition deal, while Outlook Therapeutics plummeted 56.5% after an FDA rejection and Intelligent Bio Solutions dropped 23.4% on a private placement announcement. Analysts predict modest 3-5% gains for 2026 after a record-breaking 2025.Benzinga · Jan 2, 2026

Innovations in Imaging, such as AI-Enhanced Retinal & Fundus Camera Systems are Booming Along with Revenue OpportunitiesThe retinal and fundus camera market is experiencing growth driven by the evolving landscape of imaging technologies, particularly in diagnosing age-related macular degeneration (AMD). The integration of artificial intelligence (AI) into fundus cameras presents a significant opportunity for market growth, with AI algorithms demonstrating high accuracy in detecting diseases like diabetic retinopathy (DR).GlobeNewswire Inc. · Jun 4, 2025

Outlook Therapeutics® Announces Pricing of $13.0 Million Public OfferingOutlook Therapeutics, a biopharmaceutical company, announced the pricing of a $13.0 million public offering of common stock and accompanying warrants. The company plans to use the net proceeds for working capital and general corporate purposes.Benzinga · May 23, 2025

Outlook Therapeutics® to Present at the Virtual Investor Pitch ConferenceISELIN, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that it will present at the Virtual Investor Pitch Conference on June 18, 2024 at 12:00 PM ET.GlobeNewswire Inc. · Jun 11, 2024

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMDISELIN, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the commercialization and development of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, today announced that the European Commission has granted Marketing Authorization for LYTENAVA™ (bevacizumab gamma), an ophthalmic formulation of bevacizumab for the treatment of wet AMD in the EU. LYTENAVA™ (bevacizumab gamma) is the first and only authorized ophthalmic formulation of bevacizumab for use in treating wet AMD in the EU.GlobeNewswire Inc. · May 28, 2024

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a Treatment for Wet AMDISELIN, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company working to achieve regulatory approval for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of retinal diseases in the US and Europe, today announced the submission of its Marketing Authorization Application (MAA) to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom (UK) seeking authorization of ONS-5010/LYTENAVA™ (bevacizumab gamma) for the treatment of wet age-related macular degeneration (wet AMD).GlobeNewswire Inc. · May 13, 2024

to start trading

OT

OTLKOutlook Therapeutics, Inc. Common Stock

OTLK

Pay with—

Available Balance0.00

Your PositionYou don't own any OTLK yet.

Related Tickers

Earnings